Ceria Therapeutics

Ceria therapeutics email format

Verified email-pattern data for Ceria Therapeutics is currently limited. You can still use the company insights and contact sections below.
Ceria was founded to develop products from a proprietary platform technology to treat life-threatening human diseases characterized by overactive and dysregulated immune responses. Ceria's platform technology consists of a novel active pharmaceutical agent comprised of a regulatory microRNA (miR-146a) conjugated to cerium nanoparticles (CNPs). Like all nanoparticles, CNPs are actively endocytosed by all cells they contact, delivering the miR-146a payload to targeted cells. Multiple high morbidity and life-threatening conditions are characterized by dysregulated immune responses including acute respiratory distress syndrome (ARDS), diabetic foot ulcers (DFU) and ulcerative colitis (UC), representing a US market of $4B. Affected tissues in these conditions all demonstrate reduce miR-146a and are corrected by our candidate drug products. Development to date has been supported by ~$7.5m of nondilutive financing and $500k investment capital. The company is seeking up to $3m in investment capital to contribute to a first-in-man clinical study of one drug product consisting of formulated CNP-miR-146a in DFU.
Looking for a particular Ceria Therapeutics employee's phone or email?

Ceria Therapeutics Questions

Top Ceria Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant